alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
DISMISS and Opinion Filed August 27, 2019 

S 

In The 

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-19-00259-CV 

GLORIA VALICHKOFSKY BEY, Appellant 

V. 

CHURCHILL PROPERTIES, LLC, AND MISTY POSEY, Appellees 

On Appeal from the 298th Judicial District Court 

Dallas County, Texas 

Trial Court Cause No. DC-18-07116 

MEMORANDUM OPINION 

Before Chief Justice Burns, Justice Molberg, and Justice Nowell

Opinion by Chief Justice Burns 

Appellant’s brief in this case is overdue. On July 1, 2019, we ordered appellant’s brief 

filed by July 31, 2019. When it was not filed, we notified appellant by postcard dated August 8, 

2019 and directed her to file a brief and an extension motion within ten days. We cautioned 

appellant that failure to file a brief and an extension motion would result in the dismissal of this 

appeal without further notice. To date, appellant has not filed her brief nor has she corresponded 

with the Court regarding the status of this appeal. 

Accordingly, we dismiss this appeal. TEX. R. APP. P. 38.8(a)(1); 42.3(b), (c). 

190259F.P05 

/Robert D. Burns, III/ 

ROBERT D. BURNS, III 

CHIEF JUSTICE 
 –2– 

S 

Court of Appeals 

Fifth District of Texas at Dallas 

JUDGMENT 

GLORIA VALICHKOFSKY BEY, 

Appellant 

No. 05-19-00259-CV V. 

CHURCHILL PROPERTIES, LLC, AND 

MISTY POSEY, Appellees 

 On Appeal from the 298th Judicial District 

Court, Dallas County, Texas 

Trial Court Cause No. DC-18-07116. 

Opinion delivered by Chief Justice Burns, 

Justices Molberg and Nowell participating. 

 In accordance with this Court’s opinion of this date, the appeal is DISMISSED. 

Judgment entered August 27, 2019
§ 225.80 Labeling. ( a ) Appropriate labeling identifies the medicated feed, and provides the user with directions for use which, if adhered to, will assure that the article is safe and effective for its intended purposes.
( b ) ( 1 ) Labels and labeling, including placards, shall be received, handled, and stored in a manner that prevents labeling mixups and assures that correct labeling is employed for the medicated feed.
( 2 ) Labels and labeling, including placards, upon receipt from the printer shall be proofread against the Master Record File to verify their suitability and accuracy. The proofread label shall be dated, initialed by a responsible individual, and kept for 1 year after all the labels from that batch have been used.
( 3 ) In those instances where medicated feeds are distributed in bulk, complete labeling shall accompany the shipment and be supplied to the consignee at the time of delivery. Such labeling may consist of a placard or other labels attached to the invoice or delivery ticket, or manufacturer's invoice that identifies the medicated feed and includes adequate information for the safe and effective use of the medicated feed.
( 4 ) Label stock shall be reviewed periodically and discontinued labels shall be discarded.
# Fourth Court of Appeals

**San Antonio, Texas**

JUDG MENT

No. 04

- 14

- 00206

- CV

PMSALS 1, LLC

, Appellant

v.

ROSENTHAL PAUERSTEIN SANDOLOSKI AGATHER L.L.P. and Jonathan Starr,

Appellees

From the 438th Judicial District Court, Bexar County, Texas

Trial Court No. 2013

- CI

- 17620

Honorable Olin B. Strauss, Judge Presiding

BEFORE CHIEF JUSTICE STONE

, JUSTICE ANGELINI , AND JUSTICE MARION

In accordance with this court’s opinion of this date, the joint motion to dismiss this appeal

is GRANTED, and the appeal is DI SMISSED. Costs of the appeal are taxed against the parties

who incurred them.

SIGNED October 8, 2014.

_________________________________ Catherine Stone, Chief Justice
<TABLE> <S> <C>

<PAGE>
 
<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1995
<PERIOD-END>                               OCT-01-1995
<CASH>                                           1,303
<SECURITIES>                                     2,132
<RECEIVABLES>                                    6,661
<ALLOWANCES>                                       528
<INVENTORY>                                      6,015
<CURRENT-ASSETS>                                16,576
<PP&E>                                          34,280
<DEPRECIATION>                                (18,833)
<TOTAL-ASSETS>                                  33,925
<CURRENT-LIABILITIES>                            7,290
<BONDS>                                              0
<COMMON>                                        43,162
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                    (19,692)
<TOTAL-LIABILITY-AND-EQUITY>                    33,925
<SALES>                                          9,315
<TOTAL-REVENUES>                                 9,411
<CGS>                                            6,848
<TOTAL-COSTS>                                    9,044
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                  22
<INCOME-PRETAX>                                    345
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                345
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                       345
<EPS-PRIMARY>                                      .05
<EPS-DILUTED>                                      .05
        

</TABLE>
Editorial Note on Part 25
Editorial Note: Nomenclature changes to part 25 appear at 88 FR 45065, July 14, 2023.

§ 25.42 Environmental impact statements. ( a ) As defined by CEQ regulations (40 CFR 1508.11) and section 102(2)(C) of NEPA, an EIS should be a clear, concise, and detailed written statement describing: ( 1 ) The environmental impacts of a proposed action;
( 2 ) Any adverse effects that cannot be avoided if the action is implemented;
( 3 ) Alternatives to the action;
( 4 ) The relationship between local short-term uses of the environment and the maintenance and enhancement of long-term productivity; and
( 5 ) Any irreversible and irretrievable commitments of resources that would be involved in the proposed action should it be implemented.
( b ) The CEQ regulations (40 CFR 1501.7 and part 1502) describe the process for determining the scope of an EIS and provide detailed requirements for the preparation of draft and final EIS's. CEQ format and procedures for preparing EIS shall be followed.
( c ) Under the conditions prescribed in 40 CFR 1502.9, the agency will prepare a supplement for a draft or final EIS and introduce the supplement into the administrative record.
EXHIBIT 32.1



CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350



Pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, I, Gordon Ellis, President and Chief Executive Officer, certify that:

1.

To my knowledge, this report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

To my knowledge, the information in this report fairly presents, in all material respects, the financial condition and results of operations of International Absorbents Inc. as of April 30, 2008.





|                    |                                                                     
|------------------- | --------------------------------------------------------------------
|Date: June 13, 2008 | /s/  GORDON ELLIS

Gordon EllisPresident and Chief Executive Officer
U.S. Department of Transportation

1200 New Jersey Avenue, S.E. Washington, D.C. 20590 Cairo, 21 March 2013 To Whom It May Concern,

IATA Resolution 787 regarding NDC (New Distribution Capability ) is concerned to enable the airline community to work together to modernize a data transmission standard. This will enable airlines to present content rich dy namic information on its wide range service offerings to consumers through indirect channels. Iti s worth to mention here that the airline indu stry

trend is to compete on the variety and quality of the ancillary services offered to its customers.
Airlines are unable to deliver their full product offerings to consumers through the indirect channel today

b ecause the Global Distribution Systems ( GDS s) network are based on data transmission standards that were developed prior to the Internet revolution

. This in turn undermines travel agents’ ability to meet the needs of their customers. In the same time, this limitation wastes airline efforts to present its competitive advantage in the market place. The Internet and modern data processing capabilities allow airlines to now distribute their products directly to consumers without intermediaries

. An updated data transmission standard based on XMLwil l make it easier, faster, cheaper, and much more convenient to provide the customer more information about fare alternatives, ancillary

s ervices, on board amenities and seat maps. In other words, the new data transmission will provide customers more transp arency to compare airlines products. On the customer’s privacy s ide, Resolution 787 and the NDC do not threaten airline customers’ privacy

rights , as customers will not be required to provide any more information about them than what is currently required via the GDS network. Unlike the GDS network, customer will have the option to provide personal information about themselves in return for personalized offers.

Sincerel y, Capt/ Tawfik Ass y Chairman & CEO EGYPTAIR Holding Co.
§ 212.5 To what drugs do the regulations in this part apply? ( a ) *Application solely to PET drugs.* The regulations in this part apply only to the production, quality assurance, holding, and distribution of PET drugs. Any human drug that does not meet the definition of a PET drug must be manufactured in accordance with the current good manufacturing practice requirements in parts 210 and 211 of this chapter.
( b ) *Investigational and research PET drugs.* For investigational PET drugs for human use produced under an investigational new drug application in accordance with part 312 of this chapter, and PET drugs produced with the approval of a Radioactive Drug Research Committee in accordance with part 361 of this chapter, the requirement under the act to follow current good manufacturing practice is met by complying with the regulations in this part or by producing PET drugs in accordance with Chapter 823, “Radiopharmaceuticals for Positron Emission Tomography—Compounding,” May 1, 2009, pp. 365-369, 32d ed. of the United States Pharmacopeia (USP) National Formulary (NF) (USP 32/NF 27) (2009). The Director of the Federal Register approves this incorporation by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. You may obtain a copy from the United States Pharmacopeial Convention, Inc., 12601 Twinbrook Pkwy., Rockville, MD 20852, Geeta M. Tirumalai, 301-816-8352, e-mail: *gt@usp.org ,* Internet address: *http://www.usp.org/USPNF/notices .* You may inspect a copy at the Food and Drug Administration Biosciences Library, 10903 New Hampshire Ave., Silver Spring, MD, 20993-0002, 301-796-3504, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1139 Ammonium hydroxide. ( a ) Ammonium hydroxide (NH4OH, CAS Reg. No. 1336-21-6) is produced by passing ammonia gas into water.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 20, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a leavening agent as defined in § 170.3(o)(17) of this chapter; a pH control agent as defined in § 170.3(o)(23) of this chapter; a surface-finishing agent as defined in § 170.3(o)(30) of this chapter; and as a boiler water additive complying with § 173.310 of this chapter.
( 2 ) The ingredient is used in food at levels not to exceed current good manufacturing practice. The ingredient may also be used as a boiler water additive at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52440, Nov. 18, 1983, as amended at 59 FR 14551, Mar. 29, 1994]
# EUR-Lex - 31994L0031 - EN

Avis juridique important

*|*

# 31994L0031

**Council Directive 94/31/EC of 27 June 1994 amending Directive 91/689/EEC on hazardous waste **

*
Official Journal L 168 , 02/07/1994 P. 0028 - 0028 Finnish special edition: Chapter 15 Volume 13 P. 0200 Swedish special edition: Chapter 15 Volume 13 P. 0200 *

COUNCIL DIRECTIVE 94/31/EC of 27 June 1994 amending Directive 91/689/EEC on hazardous waste

THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 130s (1) thereof,

Having regard to the proposal from the Commission (1),

Having regard to the opinion of the Economic and Social Committee (2),

Acting in accordance with the procedure laid down in Article 189 c of the Treaty,

Whereas it has become apparent, through the work of the committee provided for in Article 18 of Council Directive 75/442/EEC (3) that it has not been possible, within the time limits fixed by Directive 91/689/EEC (4), to draw up a binding list of hazardous waste, but whereas the implementation of Directive 91/689/EEC depends on the Commission's establishing such a list;

Whereas it is necessary to ensure the implementation of Directive 91/689/EEC within the shortest possible time;

Whereas a Community list of hazardous waste must still be established in accordance with Article 1 (4) of Directive 91/689/EEC;

Whereas the repeal of Council Directive 78/319/EEC of 20 March 1978 on toxic and dangerous waste (5) must therefore be postponed,

HAS ADOPTED THIS DIRECTIVE:

Article 1

Directive 91/689/EEC is hereby amended as follows:

1. The following shall be substituted for Article 10 (1):

'Article 10

1. Member States shall bring into force the laws, regulations and administrative provisions necessary for them to comply with this Directive by 27 June 1995. They shall immediately inform the Commission thereof.'

2. The following shall be substituted for Article 11:

'Annex 11

Directive 78/319/EEC shall be repealed with effect from 27 June 1995.'

Article 2

This Directive is addressed to the Member States.

Done at Luxembourg, 27 June 1994.

For the Council

The President

C. SIMITIS

(1) OJ No C 271, 7. 10. 1993, p. 16.

(2) OJ No C 34, 2. 2. 1994, p. 7.

(3) OJ No L 194, 25. 7. 1975, p. 39. Directive last amended by Directive 91/156/EEC (OJ No L 78, 26. 3. 1991, p. 32).

(4) OJ No L 377, 31. 12. 1991, p. 20.

(5) OJ No L 84, 31. 3. 1978, p. 43. Directive last amended by Directive 91/692/EEC (OJ No L 377, 31. 12. 1991, p. 48).
§ 205.5 Minimum required information for licensure. ( a ) The State licensing authority shall require the following minimum information from each wholesale drug distributor as part of the license described in § 205.4 and as part of any renewal of such license: ( 1 ) The name, full business address, and telephone number of the licensee;
( 2 ) All trade or business names used by the licensee;
( 3 ) Addresses, telephone numbers, and the names of contact persons for all facilities used by the licensee for the storage, handling, and distribution of prescription drugs;
( 4 ) The type of ownership or operation (i.e., partnership, corporation, or sole proprietorship); and
( 5 ) The name(s) of the owner and/or operator of the licensee, including: ( i ) If a person, the name of the person;
( ii ) If a partnership, the name of each partner, and the name of the partnership;
( iii ) If a corporation, the name and title of each corporate officer and director, the corporate names, and the name of the State of incorporation; and
( iv ) If a sole proprietorship, the full name of the sole proprietor and the name of the business entity.
( b ) The State licensing authority may provide for a single license for a business entity operating more than one facility within that State, or for a parent entity with divisions, subsidiaries, and/or affiliate companies within that State when operations are conducted at more than one location and there exists joint ownership and control among all the entities.
( c ) Changes in any information in paragraph (a) of this section shall be submitted to the State licensing authority as required by such authority.
(Approved by the Office of Management and Budget under control number 0910-0251)
<PAGE>
                                                                               .
                                                                               .
                                                                               .

                                                                EXHIBIT 8.1


                              List of Subsidiaries

<TABLE>
<CAPTION>

DIRECT HOLDINGS                             % HELD     STATUS      COUNTRY OF INCORPORATION
---------------                             ------     ------      ------------------------
<S>                                         <C>        <C>         <C>
Protherics Molecular Design Limited           100      trading     England and Wales
Protherics Inc.                               100      trading     U.S.A. (Delaware)
Enact Pharma PLC                              100      trading     England and Wales
Proteus Biotechnology Limited                 100      dormant     England and Wales
Genethics Limited                              76      dormant     England and Wales

INDIRECT HOLDINGS

Protherics UK Limited                         100      trading     England and Wales
Protherics Australasia pty Limited            100      trading     Australia
Protherics Utah Inc.                          100      trading     U.S.A. (Delaware)
Protherics Services pty Limited               100      trading     Australia
Kymed GB Limited                              100      dormant     England and Wales
Enzacta R&D Limited                            99.8    dormant     England and Wales
DeMontford Biopharma Limited                  100      dormant     England and Wales
Enzacta Limited                                99.8    dormant     England and Wales
TAb (Wales) Limited                           100      dormant     England and Wales
TAb (London) Limited                          100      dormant     England and Wales
Polyclonal Antibodies Limited                 100      dormant     England and Wales

</TABLE>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Justice

                    In accordance with Section 8 of the Voting Rights Act, 42 U.S.C. 1973f, I hereby certify that in my judgment the appointment of Federal observers is necessary to enforce the guarantees of the Fourteenth and Fifteenth Amendments of the Constitution of the United States in Williamson County, Texas. This county is included within the scope of the determinations of the Attorney General and the Director of the Census made under Section 4(b) of the Voting Rights Act, 42 U.S.C. 1973b(b), and published in the                     **Federal Register**                     on September 23, 1975 (40 FR 43,746).                

Dated: February 23, 2010.

Eric H. Holder Jr.,

Attorney General of the United States.

[FR Doc. 2010-3998 Filed 2-25-10; 8:45 am]

BILLING CODE 4410-13-P
<partyblock><br><br><div align="center"><b><font size="+1">The People of the State of New York, Respondent,<br><br>against<br><br>Lamont Wilson, Defendant-Appellant.</font></b></div><br><br><p>Defendant appeals from a judgment of the Criminal Court of the City of New York, New York County (Ann E. Scherzer, J.), rendered September 23, 2016, convicting him, upon a plea of guilty, of aggravated unlicensed driving in the third degree, and sentencing him to a $500 fine.</p><p>Per Curiam.</p><p>Judgment of conviction (Ann E. Scherzer, J.), rendered September 23, 2016, affirmed.</p><p>We are unpersuaded that the bargained-for sentence imposed upon defendant's conviction for aggravated unlicensed driving - payment of a $500 fine - was unduly harsh or excessive, and find no extraordinary circumstances warranting a reduction of the sentence in the interest of justice <i>(</i>see <i>People v Fair</i>, 33 AD3d 558, 558 [2006], <i>lv denied</i> 8 NY3d 945 [2007]). The defendant was sentenced in accordance with his bargained-for plea and should not now "be heard to complain that he received what he bargained for" (<i>id. </i>at 558, quoting <i>People v Chambers</i>, 123 AD2d 270, 270 [1986]). Although defendant now claims that he is indigent, he never sought relief from the fine by way of a CPL 420.10(5) motion for re-sentencing (<i>see People v Toledo</i>, 101 AD3d 571 [2012], <i>lv denied </i>21 NY3d 947 [2013]). Our disposition is without prejudice to such a motion being made by defendant.</p><p>THIS CONSTITUTES THE DECISION AND ORDER OF THE COURT.</p><br>I concur I concur I concur<br>Decision Date: January 14, 2019<br><br><div align="center"><form method="LINK" action="../../slipidx/at_1_idxtable.shtml"><input type="submit" value="Return to Decision List"></form></div></partyblock>
[if !vml]>[endif]>

[if !vml]>[endif]>

You have reached the FederalDepository Library Program Electronic Collection (FDLP/EC) Archive. Thisarchive assures ongoing access to publications in the FDLP/EC. Access to publicationsin the archive is available through GPO's suite of cataloging and locatorservices, including the Catalog of U.S. Government Publications (CGP). Archived copies of publications are retrieved in the event that publicationsare no longer available from the original publishing agency site. 
**Title:**UnitedStates Geological Survey Alaska program
 
1973 |1974 | 1975
 
SuDoc Number:I 19.4/2:
Item Number:0620-A
CGP systemNumber:000137669
April 24, 2019